ResMed vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ResMed Inc (RMD)

Q3 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

August 20267 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Latest7 Jul – 15 Sep 2026

▼3▲1

ResMed's growth slows as margins shrink and ventilator recall bites

Margin squeeze hits profits ResMed's operating margin fell to 30.7% from 33.7% a year earlier, and free cash flow margin dropped sharply. Higher research, supply chain and marketing costs, plus a $42 million safety charge, mean the company keeps less profit from each sale, which pushed shares down.
Margin decline is the core reason the stock dropped after earnings and is a key concern for future profitability.
Ventilator recall cuts sales ResMed suspended sales of its Astral ventilators after a serious safety recall. This removes about $75 million of expected revenue in fiscal 2027 and is a main reason the company's revenue forecast came in below what analysts expected, weighing on the stock.
The recall is a concrete, quantified headwind that directly explains the softer guidance and negative price reaction.
Soft FY27 guidance disappoints ResMed guided fiscal 2027 revenue to $5.75–$5.85 billion, below the $5.92 billion consensus. The shortfall, blamed on the ventilator recall and macro uncertainty like inflation in components and freight, caused a 7% share drop as investors worried about slower growth.
Guidance below expectations is a direct driver of the negative stock reaction and sets the growth outlook.
Divestiture and buybacks support focus ResMed is selling its MatrixCare software unit to Frazier Healthcare and buying Noctrix to expand into restless legs syndrome. It also raised its dividend 10% and plans over $1.85 billion in shareholder returns, including a $450 million accelerated share repurchase, signaling confidence and sharper focus on core sleep and respiratory care.
These capital actions show management's efforts to streamline and return cash, offering a positive counterweight to the margin and recall issues.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.